Qventus

Qventus Competitive Intelligence & Landscape

qventus.com ·

Overview

Qventus Overview

Qventus is a leading provider of care operations automation technology, primarily serving the healthcare industry. Founded in 2012 and headquartered in Mountain View, California, the company leverages artificial intelligence (AI) to automate hospital operations, reduce administrative burdens, and improve patient care outcomes (Exa). Its core products include AI-powered solutions that help health systems identify operational issues, suggest interventions, and take proactive actions, thereby enhancing efficiency and reducing costs (Qventus).

Qventus targets hospitals and health systems seeking to optimize their operational workflows, increase capacity, and achieve better financial and clinical results. The company's services are designed to support care teams and executives by providing powerful insights and automating routine tasks, which helps to address longstanding operational challenges in healthcare settings (Exa).

With a workforce of approximately 206 employees and a strong financial backing—total funding reaching around $203 million—Qventus has established itself as a significant player in healthcare technology. Its mission centers on transforming hospital operations through innovative AI solutions that enable healthcare providers to deliver exceptional care while maintaining financial sustainability (6sense). As of 2026, the company continues to expand its product offerings and market presence, emphasizing its commitment to improving healthcare delivery through data-driven decision-making and automation (Exa).

Qventus

Qventus Weekly Intel Updates

Receive weekly intel updates about Qventus straight to your inbox.

Competitors

Qventus Competitors

LeanTaaS is a prominent competitor to Qventus, specializing in hospital operations optimization through its cloud-based solutions like iQueue, which leverage predictive analytics and machine learning to improve patient access, reduce wait times, and lower healthcare costs. LeanTaaS has a significant market share, especially among large health systems in the U.S., and is known for its data-driven approach that enhances operational efficiency (VentureRadar). Its key differentiator is its focus on integrating lean principles with AI to optimize hospital workflows, making it a strong choice for large health systems seeking scalable solutions. Compared to Qventus, LeanTaaS emphasizes operational analytics and capacity management, with a broad market presence and high adoption rates.

OM1 is another competitor that primarily focuses on outcomes measurement and predictive analytics using big clinical data and AI, aiming to improve clinical and financial outcomes through personalized healthcare insights. Founded in 2015, OM1 is distinguished by its emphasis on data standardization and outcomes-based decision-making, positioning itself as a leader in outcomes analytics rather than operational automation (VentureRadar). While Qventus concentrates on hospital operational efficiency, OM1 targets value-based care and clinical decision support, making it more specialized in outcomes rather than day-to-day hospital operations.

Hippocratic AI is a newer player that leverages advanced AI to automate and optimize hospital workflows, including surgical scheduling and resource allocation. Recognized for its cutting-edge AI automation, it competes directly with Qventus by offering intelligent solutions that enhance hospital efficiency and reduce operational costs (LeadIQ). Its key differentiator is its focus on AI-powered automation, which appeals to health systems looking to modernize with the latest technology. Compared to Qventus, Hippocratic AI emphasizes AI innovation and automation, targeting hospitals eager to incorporate the newest AI capabilities.

Epic Systems is a dominant player in healthcare software, especially known for its electronic health records (EHR) systems. While not a direct competitor in operational automation, Epic's OR scheduling and resource management modules compete with Qventus in the surgical operations domain. Epic's market position is bolstered by its extensive customer base and integrated platform, offering comprehensive solutions that combine clinical and operational data (Elion). Unlike Qventus, which specializes in AI-driven operational workflows, Epic provides a broader healthcare IT ecosystem, making it a key player for hospitals seeking integrated clinical and operational management.

Product & Pricing

Qventus Product and Pricing Intelligence

As of March 2026, detailed information about Qventus' specific product pricing plans, tiers, and features is not explicitly outlined in the available search results. However, it is clear that Qventus offers an AI-driven platform focused on hospital operations, including discharge planning and inpatient capacity management, which automates workflows and reduces hospital length of stay (Qventus).

Qventus emphasizes its AI platform's ability to create capacity, streamline discharge processes, and improve patient flow, with features embedded directly into hospital EHR systems. While exact pricing tiers or plans are not publicly disclosed, the platform is positioned as a comprehensive solution for healthcare providers seeking operational efficiencies and capacity management (Qventus, Qventus).

Recent updates and industry recognition suggest Qventus is expanding its market presence, supported by significant funding and strategic partnerships, but specific recent pricing changes or tier structures remain unlisted in the search results. For precise pricing details, direct contact with Qventus or a demo request is typically recommended, as is common with enterprise healthcare solutions (LeadIQ).

Ad Campaigns

Qventus Ad Campaigns

Qventus is currently running 372 ads across Google, LinkedIn — 2 on Google and 370 on LinkedIn. Explore Qventus's live ad creative, messaging, and the platforms they advertise on in the ad library — updated automatically by ForesightIQ.

See of Qventus's ads

View ads

Hiring & Layoffs

Qventus Hiring and Layoffs

As of March 2026, Qventus continues to demonstrate strong growth and strategic hiring practices, reflecting its focus on expanding its leadership and operational capacity. The company recently expanded its leadership team by hiring a Chief Commercial Officer, Jeff Evans, in March 2025, following a significant Series D funding round of $105 million led by KKR, which valued the company at $1.2 billion (Qventus news). This indicates a strategic emphasis on scaling enterprise growth and strengthening market presence.

In terms of hiring trends, Qventus is actively recruiting for roles that support its mission to simplify healthcare operations through AI-driven solutions. The company’s workforce is estimated to be around 102 employees as of late 2025, with a focus on health system innovations and care automation (Built In). The company’s hiring patterns suggest a focus on high-impact, growth-oriented roles that align with its strategic goals of expanding its customer base and technological capabilities.

While there are no reports of layoffs, the company's recent funding and leadership expansion signal a positive outlook and an aggressive growth strategy aimed at increasing market share in healthcare AI. The company's ongoing investments in leadership and technology development underscore its commitment to innovation and long-term growth in the healthcare technology sector (Business Insider Africa).

Leadership

Qventus Management and Leadership Team

The leadership team of Qventus is composed of experienced executives who play a pivotal role in driving the company's growth and innovation in healthcare operations. The co-founder and CEO is Mudit Garg, who has been leading the company since its inception, supported by co-founder and CTO Ian Christopher (theorg, qventus.com).

Recent leadership changes include the appointment of Jeff Evans as Chief Commercial Officer in March 2025, a move aimed at accelerating enterprise growth following a $105 million Series D funding round led by KKR (qventus.com). This addition signifies a strategic focus on scaling the company's commercial efforts.

The company's board includes notable members such as Shahab Vagefi, along with advisors like Ursheet Parikh and Steve Kraus (theorg). The leadership team also features key executives such as Pat Saxman (Chief Revenue Officer), Mike Levin (VP, Finance), and Julie McCorkle (VP & Head, People), among others. These leaders are instrumental in shaping Qventus's strategic direction and operational excellence (theorg). Overall, Qventus continues to strengthen its executive team to support its mission of transforming healthcare operations through AI-driven solutions.

Financials

Qventus Financial Performance, Fundraising, M&A

Qventus has demonstrated significant financial growth and investment activity in recent years. In 2023, the company achieved a revenue of $21.8 million, reflecting its expanding presence in healthcare automation (getlatka). As of early 2025, Qventus secured a substantial Series D funding round of $105 million led by KKR, which valued the company at over $400 million, marking a notable increase from its previous valuation of around $200 million in 2022 (techcrunch). This funding round included participation from prominent investors such as Bessemer Venture Partners and strategic health system partners like Northwestern Medicine, HonorHealth, and Allina Health (qventus). Additionally, Qventus has raised a total of approximately $201 million across six funding rounds since its inception in 2012 (tracxn). The company's financial health appears robust, supported by strong revenue growth, high-profile investments, and strategic partnerships, positioning it as a leading player in AI-driven healthcare solutions.

Partnerships

Qventus Partnerships, Clients and Vendors

Qventus has established notable partnerships with leading healthcare systems, including Ardent Health Partners and Allina Health. In 2024, Ardent Health Partners adopted Qventus’ AI-powered solutions to optimize its perioperative operations, resulting in improved surgical access and a significant ROI of 7x annually (Qventus). Similarly, in 2025, Allina Health expanded its collaboration with Qventus through the AI Solution Factory, a co-development model designed to create tailored AI solutions for inpatient capacity and perioperative care, aiming to enhance operational efficiency and surgical growth (Qventus).

Qventus has also secured strategic investments from prominent healthcare organizations such as Northwestern Medicine, HonorHealth, and HonorHealth, which are also customers, indicating a strong ecosystem relationship (TechCrunch). The company’s recent Series D funding round raised $150 million, bringing its valuation to $1.2 billion, further demonstrating its growing influence and credibility within the healthcare AI ecosystem (Salestools). Additionally, Qventus integrates with various healthcare technology systems, automating care operations such as surgical scheduling, inpatient/outpatient workflows, and discharge processes, which are critical to its client success stories (Customer Success Stories). Overall, Qventus’ ecosystem is characterized by strategic partnerships, enterprise client relationships, and integrations that leverage AI to transform healthcare operations.

Events

Qventus Event Participations

Qventus actively participates in the healthcare industry through hosting and attending major events, including conferences, trade shows, webinars, and community gatherings. While specific details about all their participations are not explicitly listed in the search results, it is clear that Qventus is involved in industry-leading healthcare events, such as the World Health Expo, which is the largest network of healthcare events globally, connecting industry leaders, innovators, and healthcare professionals across 15 international events (worldhealthexpo.com).

Additionally, Qventus is known for its presence at healthcare conferences where it showcases its AI-powered automation solutions for hospital operations, trusted by numerous healthcare organizations (qventus.com). Although specific webinars or community events are not detailed in the search results, their active engagement in industry conferences like the World Health Expo indicates a strong presence in key healthcare industry gatherings, either as an attendee, sponsor, or host (qventus.com)).

Frequently Asked Questions

What does Qventus's appointment of a Chief Commercial Officer in March 2025 signal about its commercial maturity and next phase?

The hire of Jeff Evans as Chief Commercial Officer immediately following the $105 million Series D led by KKR indicates Qventus is transitioning from a product-led growth phase into a structured enterprise sales motion. Prior to this appointment, the company lacked a dedicated CCO, suggesting commercial execution was more founder- or CRO-driven. Pairing a CCO hire with a unicorn-level funding round ($1.2 billion valuation per some reports) points to an aggressive push to scale enterprise contracts and expand wallet share within existing health system relationships.

Does Qventus's Series D valuation hold up under scrutiny, or is there a discrepancy worth flagging?

There is a notable discrepancy in the available data: TechCrunch reported the January 2025 Series D at $105 million on a roughly $400 million post-money valuation, while other sources cite $150 million raised and a $1.2 billion valuation. The $21.8 million in 2023 revenue makes a $1.2 billion valuation (~55x revenue) aggressive even by healthcare AI standards, whereas a $400 million valuation (~18x revenue) is more defensible. Corp-dev teams should treat the higher figure with caution until audited financials or a credible secondary source confirms it.

What does Qventus's AI Solution Factory model with Allina Health reveal about its product and partnership strategy?

The AI Solution Factory, announced in 2025 with Allina Health as its inaugural client, is a co-development model where Qventus builds tailored AI solutions for inpatient capacity and perioperative care alongside the health system. This is a strategic shift from selling a standardized platform to embedding Qventus deeply into a customer's workflows as a co-development partner, which raises switching costs and can generate referenceable IP. It also signals that Qventus is using large health system relationships as R&D partnerships to accelerate product breadth without fully bearing the development cost.

What does Qventus's revenue trajectory relative to its total funding suggest about its path to profitability?

With $21.8 million in 2023 revenue against approximately $201 million in total funding raised since 2012, Qventus is carrying a heavy capital load relative to recognized revenue — a ratio that flags either a long sales cycle, significant implementation costs, or a SaaS model still in the early stages of ARR compounding. The company has not disclosed profitability metrics, so it is unclear how much of its burn is investment in growth versus structural inefficiency. The KKR-led Series D suggests institutional investors see a credible scaling path, but the revenue-to-funding ratio warrants scrutiny in any acquisition or investment diligence.

What competitive threat does Epic Systems pose to Qventus, and how is Qventus positioning to defend against it?

Epic's OR scheduling and operational analytics modules compete directly with Qventus in the perioperative and inpatient workflow domains, and Epic's deeply entrenched EHR relationships give it a significant distribution advantage. Qventus's defense appears to be EHR-agnostic AI automation embedded within existing systems — including Epic — rather than replacement, positioning itself as a workflow intelligence layer on top of the EHR rather than a competing system. The 7x annual ROI reported by Ardent Health and the co-development model with Allina Health are designed to build the outcome-validated case studies needed to justify a standalone vendor relationship even when Epic offers adjacent functionality.

What does it mean strategically that Northwestern Medicine, HonorHealth, and Allina Health are both investors and customers in the Series D?

Health system co-investors in a vendor's funding round typically signals high confidence in ROI from direct operational experience, and it creates a structural alignment of incentives — these organizations want Qventus to succeed commercially because their own operations depend on it. For competitors, this is a warning sign: these three systems are unlikely to run competitive evaluations against Qventus in the near term, and they serve as credibility anchors for Qventus's enterprise sales conversations with other health systems. For corp-dev teams, it also means any acquisition of Qventus would need to account for these strategic investor relationships, which could complicate a deal or add upside depending on acquirer intent.

How does Qventus's focus on perioperative and inpatient capacity automation differentiate it from LeanTaaS, and where do the two overlap most dangerously?

LeanTaaS's iQueue platform and Qventus's perioperative solutions overlap most directly in OR scheduling optimization and hospital capacity management — both use predictive analytics to improve surgical throughput and bed utilization. The key differentiation is that Qventus emphasizes agentic AI automation that takes proactive actions within workflows (e.g., automated discharge planning triggers), while LeanTaaS leans more heavily on operational analytics and dashboards that surface insights for human decision-makers. The danger zone for Qventus is large health systems already using LeanTaaS for capacity management, where the incremental value proposition of adding Qventus must justify a second vendor relationship and integration cost.

With a headcount estimated between 102 and 206 employees, what does the workforce size ambiguity say about Qventus's operational transparency?

The wide range in reported headcount — 102 per one source, 206 per another — reflects limited public disclosure from Qventus and reliance on third-party estimation tools, which is common for private companies of this stage. What it does confirm is that Qventus is operating with a relatively lean team for a company that has raised over $200 million, which could indicate high revenue per employee efficiency, a heavy reliance on automated delivery models, or a significant portion of implementation work handled by health system partners. For competitive intelligence purposes, the ambiguity underscores that any workforce or cost structure analysis should be treated as directional, not precise.

What does Qventus's hiring of a CCO alongside retaining a separate Chief Revenue Officer suggest about its internal commercial structure?

The co-existence of Jeff Evans as CCO and Pat Saxman as CRO suggests Qventus is building a two-tier commercial structure: the CRO likely owns near-term revenue execution and quota-carrying sales teams, while the CCO is positioned to own broader commercial strategy, partnerships, pricing architecture, and market expansion — functions that become critical as the company scales toward enterprise and potentially toward a liquidity event. This structure is typical of companies preparing for either a significant revenue scaling phase or an IPO/acquisition process where investors want both operational sales leadership and a strategic commercial vision articulated at the C-suite level.

What does Ardent Health's reported 7x annual ROI from Qventus's perioperative solution imply about Qventus's pricing power and contract size?

A 7x annual ROI claim, if substantiated, implies that Qventus is either priced conservatively relative to the value it delivers or that perioperative inefficiency in mid-to-large health systems is severe enough to make the ROI mathematics straightforward. From a pricing power standpoint, a vendor generating 7x returns has significant room to raise contract values over renewal cycles without losing the economic case for the customer. For corp-dev teams, high reported ROI at reference customers is a leading indicator of net revenue retention potential, which is a key valuation driver if Qventus pursues a public offering or strategic sale.

Does Qventus's event strategy — primarily World Health Expo and major healthcare conferences — reflect a brand-building focus or direct pipeline generation?

Qventus's conference presence, including the World Health Expo which spans 15 international events, appears oriented toward brand credibility and ecosystem visibility rather than transactional lead generation. Enterprise healthcare AI sales cycles are long and relationship-driven, so conference participation primarily serves to maintain visibility with C-suite health system executives and reinforce the company's positioning as a legitimate, scaled player. The absence of reported proprietary hosted events or a documented webinar series suggests Qventus has not yet built a major content-led pipeline engine, which could be a gap as competitors invest more heavily in thought leadership to influence evaluation criteria.

Given that Qventus doesn't publicly disclose pricing, what can be inferred about its go-to-market model and deal structure?

The absence of public pricing is consistent with a high-touch enterprise sales model where contract values are negotiated based on health system size, number of facilities, use case scope, and expected ROI — a structure common among companies targeting large hospital systems with six- or seven-figure annual contract values. The co-development AI Solution Factory model with Allina Health further confirms that deal structures are custom rather than standardized, which supports higher revenue per customer but limits the speed of self-serve or mid-market expansion. For competitive intelligence purposes, this means pricing intelligence must come from customer interviews or contract disclosures rather than public sources.

Powered by ForesightIQ · Competitive intelligence from digital exhaust